R
Richard E. Champlin
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1500
Citations - 73470
Richard E. Champlin is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 138, co-authored 1402 publications receiving 66917 citations.
Papers
More filters
Journal ArticleDOI
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients Aged 65 Years or Older with AML and MDS.
Marcos de Lima,Munir Shahjahan,J. Alamo,Patricia Williams,Brigitte von Wolff,Daniel R. Couriel,Issa F. Khouri,Gabriela Rondon,Brandy Wheeler,Elihu H. Estey,Naoto T. Ueno,Partow Kebriaei,Richard E. Champlin,Sergio Giralt +13 more
TL;DR: In this cohort with advanced stage disease (80% with active disease at transplant), NRM was high, but survival after sibling and unrelated donor transplants was similar, indicating that allogeneic HSCT is a treatment option for selected patients in this age range.
Journal ArticleDOI
Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial.
Rohtesh S. Mehta,Roland L. Bassett,Amanda Olson,Julianne Chen,Sairah Ahmed,Amin M. Alousi,Paolo Anderlini,Gheath Alatrash,Qaiser Bashir,Stefan O. Ciurea,Chitra Hosing,Jin S. Im,Partow Kebriaei,Issa F. Khouri,David Marin,Jeffrey J. Molldrem,Yago Nieto,Betul Oran,Katayoun Rezvani,Muzaffar H. Qazilbash,Samer A. Srour,Elizabeth J. Shpall,Borje S. Andersson,Richard E. Champlin,Uday R. Popat +24 more
TL;DR: The safety of timed-sequential administration of myeloablative busulfan with fludarabine (Bu-Flu) in HCT reduces relapse, but is precluded in older patients and those with high comorbidities in whom outcomes remain disappointing.
Journal ArticleDOI
Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma.
Muzaffar H. Qazilbash,Rima M. Saliba,Ana Aleman,Xiudong Lei,Donna M. Weber,Antonio Carrasco,Richard E. Champlin,Sergio Giralt +7 more
TL;DR: It is concluded that high tumor mass at diagnosis predicts a significantly shorter remission duration for myeloma patients undergoing autografting.
Journal Article
Allogeneic hematopoietic transplantation for indolent lymphomas: improved outcome with non-myeloablative versus high dose chemotherapy (HDCT) regimens
Issa F. Khouri,Rima M. Saliba,Sergio Giralt,Fredrick B. Hagemeister,Martin Korbling,Anas Younes,James Gajewski,Naoto T. Ueno,Paolo Anderlini,Fernando Cabanillas,Richard E. Champlin +10 more
Journal ArticleDOI
Safety Analysis of Intra-Patient Dose- Study of Crenolanib Maintenance Therapy in Patients with FLT3 Mutant AML Following Allogeneic Hematopoietic Stem Cell Transplant
Betul Oran,Stefan O. Ciurea,David Marin,Jessica McCarty,Qaiser Bashir,Sairah Ahmed,Amanda Olson,Uday R. Popat,Yago Nieto,Partow Kebriaei,Elizabeth J. Shpall,Trishala Agrawal,Richard E. Champlin +12 more
TL;DR: The outcomes of safety and tolerability of crenolanib maintenance in FLT3 mutant AML patients after allo-HSCT (NCT02400255) are reported and side effects were predominantly grade 1 and 2.